MedTrace Logo

Monitoring Drug Efficacy in Patients with Alzheimer's Disease

NCT05801380 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-01-07

No results posted yet for this study

Summary

This study will explore the different factors associated with drug response to acetylcholinesterase (AChE) inhibitor (donepezil) and NMDA receptor antagonist (memantine) in patients with Alzheimer's Disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

AChE inhibitor monotherapy

This is a drug treatment using Donepezil only

DRUG

AChE inhibitor and NMDA receptor antagonist combination therapy

This is a drug treatment combining Donepezil and Memantine

Sponsors & Collaborators

  • University of the Philippines

    lead OTHER

Principal Investigators

  • Fresthel Monica M Climacosa, MD, PhD · University of the Philippines Manila

  • Veeda Michelle M Anlacan, MD · University of the Philippines Manila

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-14
Primary Completion
2026-02-14
Completion
2026-02-14

Countries

  • Philippines

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05801380 on ClinicalTrials.gov